Supporting EU Pharma Success: A GTM Milestone

A prominent global pharmaceutical firm sought to launch a breakthrough biologic therapy in the highly regulated and competitive European Union market. The challenge was multi-faceted: navigating divergent healthcare systems, meeting rigorous regulatory standards, aligning with payer expectations, and ensuring rapid HCP adoption across six key EU countries.

Mar8Access developed and executed a customized Go-To-Market (GTM) plan that included deep competitor intelligence, market-specific opportunity sizing, stakeholder mapping, and KOL engagement strategy. Our regulatory affairs specialists ensured that all messaging was compliant with EMA guidelines while tailored to the nuances of each local market.

Key Deliverables:

• Country-specific GTM roadmaps and regulatory workflows
• Payer insight reports and value-based pricing recommendations
• Launch readiness scorecards with KPIs tied to adoption benchmarks
• Engagement strategy with EU5 KOLs and specialist networks

Outcome:
The launch exceeded commercial forecasts by 17% in the first six months, with accelerated formulary inclusion and positive HCP feedback. The client credited Mar8Access with enabling a faster, more coordinated entry across complex regional markets.